No immediate threat for KIMMTRAK from Ideaya's darovasertib
Ideaya released an update for its phase 2 study of darovasertib and crizotinib combination in metastatic uveal melanoma (mUM). While ORR looked very encouraging with 45% in the first-line and mPFS tracking at 7 months, the company will initially target the HLA-A2:01-negative population as Immuncore
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.